MarketingMedicalPolicy,Access,Value, andEvidenceConsultingData,Technology,and Media
murmuration of birds
Previous
Next

thought leadership

Trends 2024: Capitalizing on the strategic opportunity of digital therapeutics for biopharma

3/7/2024

Digital therapeutics uptake continues to grow rapidly across multiple therapy areas. Our experts explore the strategic opportunities and challenges for stakeholders in the complex biopharmaceutical market.

The digital therapeutics (DTx) market, with a valuation of an estimated USD 6.2 billion in 2023, is growing rapidly as the healthcare sector trends toward innovative, technology-driven solutions.

These, which vary from user-friendly mobile health apps to sophisticated software systems integrated with biometric sensors, are making strides in addressing a wide range of health conditions. Their applications span from managing chronic diseases like diabetes to providing support for mental health conditions such as depression. In this article, we uncover the fast-evolving market opportunity for biopharmaceutical companies to leverage these healthcare innovations, including advice for navigating the risks and driving successful commercialization.

The expanding DTx market presents an opportunity for biopharmaceutical companies to launch new pharmacological treatments. Integrating DTx not only promises to streamline the therapeutic process and improve patient adherence and outcomes but also leverages the efficiency of digital platforms to collect actionable patient data, enhancing both the value and impact of pharmaceutical innovations.

This remarkable growth not only highlights the efficacy and versatility of digital therapeutics but also points to their increasing role in enhancing healthcare delivery, making treatments more personalized and systems more efficient. As the sector grows, it continues to adapt and evolve, meeting the challenges of regulatory landscapes and market access with a commitment to robust clinical validation and patient-centric care.

Fill in the form below to gain insights into:

  • Strategic opportunities for biopharmaceutical companies in the DTx space
  • Hurdles to the adoption of digital therapeutics in combination with medicines
  • Key considerations for creating optimal digital therapeutics strategies

 

How we use cookies

Cookies are files saved on your phone, tablet or computer when you visit a website.

We use cookies to store information about how you use the Fishawack Health website, such as the pages you visit.

For more information, check the cookie statement

32E8261E-A569-4B66-ACC6-3CB772DDEDEE

Cookie settings

We use 4 types of cookies. You can choose which cookies you're happy for us to use.

Cookies that measure website use.

We use Google Analytics to measure how you use the website so we can improve it based on user needs. We do not allow Google to use or share the data about how you use this site.

  • how you got to the site
  • the pages you visit on fishawack.com, and how long you spend on each page
  • what you click on while you're visiting the site

Cookies that help with our communications and marketing

These cookies may be set by third party websites and do things like measure how you view Vimeo videos that are on Fishawack.com.

Cookies that remember your settings

These cookies do things like remember your preferences and the choices you make, to personalize your experience of using the site.

Strictly necessary cookies

These essential cookies do things like remember your progress through a form (eg. Registering for new content alerts).

These cookies always need to be on.